Findings on Gout Reported by L.J. Smolen et al (The Budget Impact of Increased Use of Febuxostat in the Management of Gout: A US Health Plan Managed…
Findings on Gout Reported by
By a
Our news journalists obtained a quote from the research, "A US payer-perspective budget impact model followed ULT patients from a 1,000,000 member plan over 3 years. The current market share scenario, febuxostat (6%) and ULT allopurinol (94%), was compared with an 18% febuxostat market share. Data were implemented from randomized controlled trials, census and epidemiologic studies, and real-world database analyses. An innovation was the inclusion of gout-related chronic kidney disease costs. Cost results were estimated as annual and cumulative incremental costs, expressed as total costs, cost per member per month, and cost per treated member per month. Clinical results were also estimated. Increasing the febuxostat market share resulted in a 6.3% increase in patients achieving the sUA target level of <6.0 mg/dL and a 1.4% reduction in gout flares during the 3-year period. Total cost increased 1.4%, with a 49.9% increase in ULT costs, a 1.4% reduction in flare costs, a 1.2% reduction in chronic kidney disease costs, and a 2.8% reduction in gout care costs. The cumulative incremental costs were
According to the news editors, the research concluded: "Expanded use of febuxostat in the treatment of all gout patients, independent of renal impairment status, should be considered based on improved clinical outcomes and longer-term medical cost savings associated with these improved outcomes."
For more information on this research see: The Budget Impact of Increased Use of Febuxostat in the Management of Gout: A
Our news journalists report that additional information may be obtained by contacting
Keywords for this news article include:
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2016, NewsRx LLC
Studies from Heart Institute Describe New Findings in Cardiovascular Diseases (Impact of the 2013 Cholesterol Guideline on Patterns of Lipid-Lowering…
Advisor News
Annuity News
Health/Employee Benefits News
Life Insurance News